Compare · HEPA vs NVO
HEPA vs NVO
Side-by-side comparison of Hepion Pharmaceuticals Inc. (HEPA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HEPA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $167.46B.
- Over the past year, HEPA is up 0.0% and NVO is down 16.0% - HEPA leads by 16.0 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 2 for HEPA).
- NVO has more recent analyst coverage (25 ratings vs 1 for HEPA).
- Company
- Hepion Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- -
- $167.46B
- 1M return
- +0.00%
- -4.16%
- 1Y return
- +0.00%
- -15.97%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 7
- Recent ratings
- 1
- 25
Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HEPA
- Amendment: SEC Form 10-Q/A filed by Hepion Pharmaceuticals Inc.
- SEC Form 10-Q filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S